UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response...

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Tepper Mark			2. Issuer Name and Ticker or Trading Symbol Corbus Pharmaceuticals Holdings, Inc. [CRBP]						5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 03/01/2017							Director 10% Owner Other (give title below) Other (specify below) President and CSO				
				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person				
NORWOOD, MA 02062 (City) (State) (Zip)			Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Securit (Instr. 3)	nstr. 3) Date			2A. Deemed 3. Transa Execution Date, if Code		ransade r. 8)	etion 4. (A	Securities Acq or Disposed astr. 3, 4 and 5) (A) or nount (D)	Scquired 5. Amour Owned For Transaction (Instr. 3 a		mount of Securities Beneficially and Following Reported assection(s) r. 3 and 4)		5. 7. Ownership of Form: B	eneficial wnership	
Reminder: Repor	rt on a sepa	rate line for each cl	Table II - l	Derivative	Securi	ties Acc	quire	Persons in this fo a curren	who respon orm are not re tly valid OMI ed of, or Bene vertible securi	equired B contro	to respond ol number.				74 (9-02)
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	e (Month/Day/Year)	3A. Deemed Execution Date, it	4. If Transaction Code		5. Number of									
Derivative C Security (Instr. 3)	or Exercise Price of Derivative	Date	Execution Date, i any	Code	tion De Second or of (In	curities equired (Dispose (D) sstr. 3, 4	(A)	6. Date Ex Expiration (Month/D		7. Title of Und Securit	e and Amount derlying ties 3 and 4)		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	Ownership Form of Derivative Security: Direct (D) or Indirect s) (I)	
Derivative C Security (Instr. 3)	or Exercise Price of Derivative	Date	Execution Date, i any	Code	tion De See) Ac or of (In and	rivative curities quired (Dispose (D) str. 3, 4	(A) ed	Expiration	a Date ay/Year) Expiration	7. Title of Und Securit	derlying ties	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Ownership Form of Derivative Security: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)

Reporting Owners

Bernardia Commun Name / Addison	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Tepper Mark C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 100 RIVER RIDGE DRIVE NORWOOD, MA 02062			President and CSO			

Signatures

/s/ Mark Tepper	03/03/2017
Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vests on March 1, 2018, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on April 1, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.